Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 12/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16907850 | 0.89 | IRAK4 (0.57) | IRAK4IRAK1 | |
| SCHEMBL15416036 | 0.83 | IRAK4 (0.51) | IRAK4IRAK1 | |
| SCHEMBL15416466 | 0.82 | IRAK4 (0.58) | IRAK4IRAK1 | |
| SCHEMBL20262248 | 0.82 | IRAK1 (0.46) | IRAK4IRAK1 | |
| SCHEMBL15416393 | 0.81 | IRAK1 (0.56) | IRAK4IRAK1MET | |
| SCHEMBL16899706 | 0.81 | IRAK1 (0.45) | IRAK4IRAK1 | |
| SCHEMBL15416616 | 0.81 | IRAK4 (0.52) | IRAK4IRAK1 | |
| SCHEMBL15431525 | 0.79 | IRAK4 (0.58) | IRAK4IRAK1 | |
| SCHEMBL15431494 | 0.79 | IRAK4 (0.48) | IRAK4IRAK1 | |
| SCHEMBL15416640 | 0.78 | IRAK1 (0.59) | IRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | MERCK PATENT GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3092225-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | Merck Patent GmbH (DE) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106058-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK1 3/4885MET 2313/4885 |
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK1 3/4885MET 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.